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ABSTRACT
Background: Flavonoids inhibit the growth of colon cancer cells in
vitro. In a secondary analysis of a randomized controlled trial, the
Polyp Prevention Trial, a higher intake of one subclass, flavonols,
was statistically significantly associated with a reduced risk of recurrent
advanced adenoma. Most previous prospective studies on colorectal
cancer evaluated only a limited number of flavonoid subclasses and
intake ranges, yielding inconsistent results.
Objective: In this study, we examined whether higher habitual die-
tary intakes of flavonoid subclasses (flavonols, flavones, flavanones,
flavan-3-ols, and anthocyanins) were associated with a lower risk of
colorectal cancer.
Design: Using data from validated food-frequency questionnaires
administered every 4 y and an updated flavonoid food composition
database, we calculated flavonoid intakes for 42,478 male partici-
pants from the Health Professionals Follow-Up Study and for 76,364
female participants from the Nurses’ Health Study.
Results: During up to 26 y of follow-up, 2519 colorectal cancer cases
(1061 in men, 1458 in women) were documented. Intakes of flavonoid
subclasses were not associated with risk of colorectal cancer in either
cohort. Pooled multivariable adjusted RRs (95% CIs) comparing the
highest with the lowest quintiles were 1.04 (0.91, 1.18) for flavonols,
1.01 (0.89, 1.15) for flavones, 0.96 (0.84, 1.10) for flavanones, 1.07
(0.95, 1.21) for flavan-3-ols, and 0.98 (0.81, 1.19) for anthocyanins (all
P values for heterogeneity by sex .0.19). In subsite analyses, flavo-
noid intake was also not associated with colon or rectal cancer risk.
Conclusion: Our findings do not support the hypothesis that a higher
habitual intake of any flavonoid subclass decreases the risk of colorectal
cancer. Am J Clin Nutr 2016;103:184–91.
Keywords: flavonoids, flavonols, flavones, flavanones, flavan-3-ols,
anthocyanins, colorectal cancer
INTRODUCTION
Flavonoids are a group of bioactive polyphenolic compounds
naturally occurring in plant-based foods such as fruits, vegeta-
bles, grains and herbs, and drinks such as tea, wine, and juices.
Based on their structure, flavonoids can be subclassified as fla-
vonols, flavones, flavanones, catechins (flavan-3-ols or flavanols),
isoflavones, anthocyanins, and oligomeric or polymeric flavo-
noids. Experimental studies have shown cancer-protective effects
of flavonoids through several biological mechanisms, including
antioxidative and anti-inflammatory properties, induction of apo-
ptosis, and inhibition of proliferation and angiogenesis (1). Spe-
cifically, flavonoids have been shown to inhibit growth of human
colon cancer cell lines in vitro and restrict colorectal carcinogenesis
in animal models (2, 3). A proportion of dietary flavonoids is
absorbed in the small intestine and reaches plasma concentrations
that could have biological effects. In addition, substantial amounts
reach the colon, where they are further metabolized intometabolites
that may also mediate some biological activity (4). Current ob-
servational studies investigating the association between flavonoid
intake and risk of colorectal cancer (CRC)12 have been in-
consistent. Although several case-control studies suggest an in-
verse association between high flavonoid intake, particularly
flavonols and anthocyanins, and CRC (5–9), prospective cohort
1 Supported by NIH grants P01 CA87969, UM1 CA186107, P01 CA55075
and UM1 CA167552 (to WCW), R01 CA151993 and R35 CA197735
(to SO), R01 CA137178 (to ATC), and P50 CA127003 (to CSF); Biotech-
nology and Biological Sciences Research Council, United Kingdom (REF:
BB/J004545/1 to AC); SDA Agricultural Research Service (agreement 58-
1950-0-0141 to AC); and Royal Society Wolfson Research Merit Award
(to AC). This is an open access article distributed under the CC-BY license
(http://creativecommons.org/licenses/by/3.0/).
2 Supplemental Tables 1–8 are available from the “Online Supporting Ma-
terial” link in the online posting of the article and from the same link in the
online table of contents at http://ajcn.nutrition.org.
*Towhom correspondence should be addressed. E-mail: katharina.
nimptsch@mdc-berlin.de.
Received June 18, 2015. Accepted for publication September 29, 2015.
First published online November 4, 2015; doi: 10.3945/ajcn.115.117507.
12Abbreviations used: CRC, colorectal cancer; FFQ, food-frequency ques-
tionnaire; HPFS, Health Professionals Follow-Up Study; NHS, Nurses’
Health Study.
184 Am J Clin Nutr 2016;103:184–91. Printed in USA.
studies have generally failed to detect an association (10–14).
However, an inverse association between catechin intake and risk
of rectal cancer has been suggested by a cohort study in women
(15). In addition, in a secondary analysis of a US-based random-
ized controlled trial, the Polyp Prevention Trial, higher intake of
flavonols was statistically significantly associated with a 76% re-
duced risk (OR: 0.24; 95% CI: 0.11, 0.53) of advanced recurrent
adenoma, a precursor for CRC (16). In the only study investigating
biomarkers of flavonoid intake in relation to CRC incidence we are
aware of, urinary catechins at baseline were inversely related to
later risk of colon cancer (17).
Dietary flavonols and flavones and CRC risk have been pro-
spectively investigated in the Health Professionals Follow-Up
Study (HPFS) and Nurses’ Health Study (NHS) previously, and no
association was observed (13). A drawback of most prospective
studies, including the previous analysis of NHS and HPFS data, is
that only a small number of flavonoid subclasses (e.g., flavonols
and flavones) were evaluated and intake ranges were limited (10–
13, 15). In the present study, we have updated our flavonoid food
composition database based on an updated and expanded USDA
database (18) to examine the association between habitual intake
of various flavonoid subclasses (i.e., flavonols, flavones, flava-
nones, flavan-3-ols, and anthocyanins) and CRC risk in the NHS
and HPFS, with longer follow-up and a larger number of incident
cases compared with the previous analysis (13), thus enabling us
to investigate long-term habitual flavonoid intake as well as fla-
vonoid intake with different latencies to better understand whether
timing of intake makes a difference.
METHODS
Study population
Details of the HPFS and NHS prospective cohorts have been
published elsewhere (19, 20). In brief, the HPFS was initiated in
1986 and included 51,529 USmale health professionals (dentists,
optometrists, osteopaths, podiatrists, pharmacists, veterinarians)
who were 40–75 y old at baseline. The NHS began in 1976,
when 121,701 US-registered female nurses aged 30–55 y pro-
vided information on their medical history and lifestyle. In both
cohorts, questionnaires were administered biennially to update
lifestyle factors and elicit new medical diagnoses. Follow-up
rates have been .90% in each 2-y cycle, and the cumulative
follow-up rate (i.e., the percentage of potentially collected
person-years) was 94% in the HPFS and 93% in the NHS. Di-
etary intake data were collected every 4 y in both the NHS and
HPFS via a mailed food-frequency questionnaire (FFQ).
In the present study, we used 1984 as baseline for the NHS and
1986 for the HPFS, the respective years in which dietary intakes
were assessed by using a validated 116- to 131-item FFQ. Among
the participants who returned the baseline FFQs, we excluded those
who had a history of cancer (except for nonmelanoma skin cancer)
or ulcerative colitis, reported very high or very low energy intakes
(,600 or .3500 kcal/d for women, ,800 or .4200 kcal/d for
men), left .70 food items blank on the FFQs, or had missing
information on flavonoid intake. After these exclusions, 76,364
women and 42,478 men were included in the analysis.
The study protocol was approved by the Institutional Review
Board at Brigham and Women’s Hospital and the Harvard
School of Public Health.
Assessment of flavonoid intake
Validated FFQs (20, 21) were administered in 1984, 1986, and
every 4 y thereafter in the NHS. In HPFS, similar FFQs were
administered in 1986 and every 4 y thereafter. In the semi-
quantitative FFQs, food and beverage items are specified by
commonly used units or portion sizes. In each FFQ, participants
were asked to report how often, on average, they consumed
a serving of each food item during the previous year with 9
possible response categories ranging from “never or less than
once per month” to “6 or more times per day.” Individual nu-
trient intakes were calculated from FFQ data by multiplying the
nutrient content per serving of each food by the indicated fre-
quency of consumption (servings of that food per day) and
summing over all foods. A database for the calculation of ha-
bitual intake of different flavonoid subclasses was developed as
has been described previously (18). For the present analysis, 5
main flavonoid subclasses (expressed as aglycones) commonly
consumed in the US diet were considered: flavonols (quercetin,
kaempferol, myricetin, isorhamnetin), flavones (apigenin,
luteolin), flavanones (eriodictyol, hesperetin, naringenin), flavan-
3-ol monomers (catechin, epicatechin, epigallocatechin, epicatechin-
3-gallate, epigallocatechin-3-gallate), and anthocyanins (cyanidin,
delphinidin, malvidin, pelargonidin, petunidin, peonidin). Total
flavonoid intakes were derived by the sum of the components
flavonols, flavones, flavanones, flavan-3-ols, anthocyanins, and
polymeric/oligomeric flavonoids (including proanthocyanidins,
theaflavins, and thearubigins). As has been described previously,
the main food sources of flavonols are tea and onions, those of
flavones and flavanones are oranges, those of flavan-3ols are tea,
those of anthocyanins are blueberries, and those of oligomeric
and polymeric flavonoids are tea, apples, and strawberries
(18, 22). Nutrient intakes were energy adjusted by the residual
method (23). To represent long-term dietary intake, we calcu-
lated cumulative average intakes for a given questionnaire cycle
by averaging the intake for the current and preceding FFQs
(24). Because FFQs administered before 1990 contained fewer
questions on some flavonoid-rich fruits and vegetables (e.g.,
onions were not listed in questionnaires before 1990), in sensi-
tivity analyses, we used 1990 as baseline for both the HPFS
and NHS.
Reproducibility and relative validity of the FFQs have been
investigated previously (25, 26). For the major food sources of
flavonoids, correlations between dietary records and FFQs in the
HPFS and NHS were as follows: 0.77–0.93 for tea, 0.83–0.90 for
red wine, 0.74–0.76 for oranges, and 0.70–0.80 for apples or
pears (25, 26). In recent analyses in the HPFS and NHS, fla-
vonoid subclasses have been associated with lower risk of
several chronic diseases, including hypertension (18), ovarian
cancer (27), and Parkinson disease (28), giving further qualita-
tive support for the ability of the FFQ to reasonably estimate
dietary intake of flavonoid subclasses.
Assessment of covariables
Information on lifestyle and other health-related factors, such
as body weight, cigarette smoking, physical activity, participation
in gastrointestinal endoscopic examinations, use of aspirin and
other nonsteroidal anti-inflammatory drugs, menopausal status,
and postmenopausal hormone use (in women only), was collected
and updated in the biennial follow-up questionnaires. Family
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history of CRC in a first-degree relative was assessed in the 1982,
1988, 1992, 1996, and 2000 questionnaires in the NHS and in the
1986, 1990, 1992, and 1996 questionnaires in the HPFS.
Ascertainment of CRC cases
In both the NHS and HPFS, participants who reported a di-
agnosis of CRC on one of the biennial follow-up questionnaires
were asked for permission to obtain their medical records and
pathologic reports. Given the colorectal continuum model (29),
we included colon cancers and rectal cancers. A study physician,
blinded to exposure information, reviewed the records to confirm
CRC diagnosis and to extract information on anatomic location,
stage, and histologic type of the cancer. The National Death Index
was queried to discover deaths and to ascertain any diagnosis of
CRC that contributed to death or was a secondary diagnosis. In
the case participants who had died of CRC were not captured
during our regular disease follow-up, we contacted next of kin to
ask for permission to obtain and review medical records to
confirm a diagnosis of CRC. Deaths of all cohort members were
identified through the National Death Index, the state vital sta-
tistics record, and death certificates that were mailed by next of
kin of deceased participants, resulting in .98% complete as-
certainment in mortality surveillance (30, 31). CRC was defined
based on the International Statistical Classification of Diseases,
Injury and Causes of Death (Ninth Revision) as a combination
of tumors of the colon (C18.0–C18.7), tumors that were over-
lapping or unspecified (C18.8–C18.9), and tumors of the rectum
(C19–C20). All cases included in the present analysis were
confirmed by medical records. Between return of the baseline
questionnaires and 2010, a total of 1458 CRC cases (1151 colon,
307 rectum) were documented in the NHS and 1061 (831 colon,
230 rectum) in the HPFS.
Statistical analysis
Each participant contributed person-time of follow-up from
the date of return of the baseline questionnaire to the date of CRC
diagnosis, death, or end of analysis follow-up (31 May 2010 for
the NHS, 31 January 2010 for the HPFS), whichever came first.
We used Cox proportional hazards regression models calculating
HRs (as an estimate of RR) and 95% CIs to quantify the asso-
ciations of habitual intake of different flavonoid subclasses with
overall and subsite-specific risk of CRC within each cohort. To
control as finely as possible for confounding by age and calendar
time, we stratified Cox models jointly by age in months at the
start of follow-up and calendar year of the current questionnaire
cycle. We tested the proportional hazards assumption by using
likelihood ratio tests comparing models with and without in-
teraction terms between flavonoid subclass variables and age or
follow-up time and did not observe any violation. Inmultivariable
models, on the basis of our knowledge from previous investigations
within the HPFS and NHS (32–34), we simultaneously adjusted for
CRC risk factors that may confound the association between fla-
vonoid subclasses and CRC risk. These factors included pack-years
of smoking before age 30 y, history of CRC in a parent or sibling,
history of lower bowel endoscopy, regular aspirin use, meno-
pausal hormone use (in women only), BMI, physical activity,
alcohol consumption, total calorie intake, vitamin D intake,
calcium intake, and consumption of red meat and processed
meat. To assess whether potential collinearity between dietary
variables may have affected our results, we also constructed
a “basic model” (35), which included all nondietary covariates,
alcohol, and total energy intake and then added each dietary
variable separately to the model. To represent long-term dietary
and lifestyle patterns, we used cumulative averages for BMI,
physical activity, regular aspirin/nonsteroidal anti-inflammatory
drug use, and dietary intakes throughout follow-up to control for
confounding in regression models. As a sensitivity analysis, we
also adjusted for the diet quality scores from the Alternate
Healthy Eating Index–2010 (36) and Dietary Approaches to Stop
Hypertension (37). Our primary exposure of interest was cumu-
lative average flavonoid intake between baseline and follow-up
period representing long-term habitual flavonoid intake and
minimizing the impact of random measurement errors in the
dietary assessment by FFQs.
In sensitivity analyses, we evaluated the possible modification
by time in the association between intake of flavonoid subclasses
and CRC incidence. For this purpose, Cox models based on
dietary data collected at different time points were constructed:
1) flavonoid intake at the beginning of follow-up, 2) recent
(simple updated) flavonoid intake reported on the most recent
FFQ before each follow-up interval (latency 0–4 y), and 3)
flavonoid intake reported at different latencies (i.e., 4–8 y, 8–12 y,
12–16 y) before diagnosis as described previously (38). For ex-
ample, for latency of 4–8 y, flavonoid intake assessed on the 1986
FFQ was related to CRC cases diagnosed between 1990 and
1994, flavonoid intake assessed on the 1990 FFQ was related to
CRC cases diagnosed between 1994 and 1998, flavonoid intake
assessed on the 1998 FFQ was related to CRC cases diagnosed
between 2002 and 2006, and so forth. Because the FFQs were
administered every 4 y, the simple updated model 2 can be
considered a 0- to 4-y latency analysis.
Intakes of flavonoid subclasses were categorized into quintiles
based on the distribution in the study population. Tests for linear
trend over quintiles were performed by assigning the median
value to each category, entering these values as a continuous
variable to the model, and evaluating its statistical significance by
using the Wald test. All analyses were conducted in the NHS and
HPFS separately, and risk estimates were pooled by using
random-effects models (39) if there was no indication of het-
erogeneity by sex. We tested whether the association between
flavonoid subclass intake and risk of CRC was modified by age
(,65 y vs. $65 y), smoking status (ever vs. never), alcohol
intake (high vs. low, based on sex-specific median value), or
physical activity (high vs. low, based on sex-specific median
value) by adding cross-product terms to the multivariable models
and employing Wald tests.
All analyses were conducted by using SAS software (version
9.3; SAS Institute Inc.). A 2-sided P value of ,0.05 was con-
sidered statistically significant.
RESULTS
Participants’ characteristics, averaged according to proportion
of person-time in each quintile of total flavonoid intake, are
shown in Table 1 (equivalent tables for intake of flavonoid
subclasses are available as Supplemental Tables 1–5). In both
men and women, physical activity was higher in participants
with high flavonoid intake than in participants in the lower
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quintiles of flavonoid intake. Dietary intakes of red meat and pro-
cessed meat were lower in the upper quintiles of flavonoid intake
than in the lower quintiles. In the HPFS, during 419,133 y of follow-
up, 1061 cases of CRC occurred (2.53 cases per 1000 person-years).
In the NHS, 1458 CRC cases were registered during 927,994
person-years of follow-up (1.57 cases per 1000 person-years).
In relation to the different flavonoid subclasses, flavonol, fla-
vone, flavanone, or flavan-3-ol intake was not associated with risk
of CRC in pooled analyses or cohort-specific analyses (Table 2).
Anthocyanin intake was statistically significantly associated with
lower risk of CRC in age-adjusted models in men (RR: 0.78; 95%
CI: 0.64, 0.94; P-trend = 0.03), which was attenuated after mul-
tivariable adjustment (RR: 0.88; 95% CI: 0.72, 1.07; P-trend =
0.35). We explored the reason for this attenuation by adding 1)
nondietary potential confounders one by one to the age-adjusted
model and 2) dietary potential confounders one by one to the
basic model (for more detail on the basic model, see Statistical
analysis section). Largest attenuations were observed after in-
dividual adjustment for physical activity, smoking before age 30 y,
and red and processed meat intake (data not shown). However, no
association between anthocyanin intake and risk of CRC was
observed in women, and there was no substantial heterogeneity
by sex (P-heterogeneity = 0.18).
When examining subsites of CRC, no association between
flavonoid subclasses and risk of colon cancer (neither proximal
nor distal colon cancer; data not shown) or rectal cancer was
observed in both cohorts.
The associations were not materially altered after additional
adjustment for Alternate Healthy Eating Index–2010 score or
Dietary Approaches to Stop Hypertension diet scores (data not
shown).
When we investigated potential effect modification in the
association between flavonoid subclass intake and risk of CRC by
age, smoking, alcohol intake, and physical activity, no statisti-
cally significant interactions were observed (all P-interaction .
0.05).
Associations between flavonoid subclasses and risk of CRC
were not modified by time—that is, no substantially different
results were obtained when flavonoid intake at beginning of
follow-up (Supplemental Table 6) or with a latency of 0–4 y,
4–8 y, or 8–12 y (Supplemental Table 7) was investigated.
The association between intake of flavonols, of which onions
are a main food source, and risk of CRC was not substantially
different when follow-up was started in 1990 (the first year
onions were specifically asked for in the FFQs) (data not
shown).
We further explored the association between main food sources
of flavonoids and risk of colorectal, colon, and rectal cancer
(Supplemental Table 8). Dietary intake of blueberries (main
food source of anthocyanins), oranges (main food source of
flavones and flavanones), or tea (main food source of flavonols
and flavan-3-ols) was not associated with risk of CRC in men
or women.
DISCUSSION
In this study comprising 2 large cohorts with .1,347,000
person-years of follow-up and 2519 CRC cases, we observed no
TABLE 1
Age-standardized characteristics of person-years according to quintiles of total flavonoid intake in the NHS and HPFS1
HPFS NHS
Q1 Q3 Q5 Q1 Q3 Q5
Age at baseline, y 51.4 6 9.32 52.4 6 9.4 52.9 6 9.3 49.3 6 7.1 50.4 6 7.1 50.1 6 7.2
BMI, kg/m2 26.3 6 3.8 25.8 6 3.5 25.7 6 3.5 26.6 6 5.5 26.1 6 5.1 26.0 6 5.0
Physical activity, METs/wk 28.3 6 35.8 35.5 6 40.5 34.8 6 40.2 13.6 6 19.3 18.2 6 22.6 18.0 6 23.1
Current/past smokers, % 10.1 4.1 4.1 22.1 10.9 11.2
Pack-years of smoking before age 30 y 11.7 6 6.7 10.7 6 6.5 10.8 6 6.6 7.5 6 5.3 6.8 6 5.4 6.9 6 5.5
Family history of CRC, % 11.0 11.8 11.7 12.9 13.3 13.4
History of endoscopy, % 19.0 21.0 21.2 18.7 20.1 19.9
Regular aspirin or NSAID use, % 39.8 40.7 40.6 41.6 41.0 42.0
Dietary intake
Alcohol, g/d 12.1 6 16.8 11.0 6 14.2 9.9 6 13.9 6.5 6 12.0 5.5 6 9.3 4.8 6 9.2
Calcium, mg/d 952 6 470 973 6 446 968 6 475 1097 6 595 1197 6 586 1184 6 610
Vitamin D, IU/d 423 6 304 451 6 301 461 6 326 395 6 303 431 6 301 433 6 313
Red meat, g/d 74.1 6 55.3 59.2 6 45.6 53.0 6 46.0 61.9 6 44.0 53.3 6 38.5 50.8 6 38.9
Processed meat, g/d 13.4 6 16.6 10.1 6 12.4 8.4 6 11.8 10.1 6 12.3 7.8 6 9.6 7.2 6 9.5
Total flavonoids, mg/d 116 6 36 267 6 33 769 6 355 107 6 62 251 6 62 808 6 390
Flavonols, mg/d 10.5 6 6.5 16.3 6 8.2 32.0 6 14.3 9.1 6 5.8 14.6 6 7.2 31.9 6 13.6
Flavones, mg/d 1.5 6 1.3 2.9 6 1.6 3.4 6 2.4 1.3 6 1.1 2.4 6 1.5 2.5 6 2.0
Flavanones, mg/d 25.9 6 23.3 57.9 6 38.3 68.9 6 59.7 21.4 6 21.2 48.7 6 35.8 49.8 6 45.5
Flavan-3-ols, mg/d 11.9 6 7.2 26.5 6 10.8 128 6 88 9.3 6 5.1 24.1 6 10.3 149.5 6 95.1
Anthocyanins, mg/d 5.5 6 5.4 14.5 6 11.1 25.5 6 36.1 5.5 6 5.4 14.6 6 11.3 22.5 6 31.6
Polymers, mg/d 60.4 6 26.3 149 6 39 517 6 279 54.1 6 23.6 141.2 6 35.5 565.8 6 301.6
1All variables (except age) are age standardized. Physical activity is described by the product sum of the MET of each specific recreational activity and
hours spent on the activity per week. Regular aspirin or NSAID use is defined as $2 standard (325-mg) tablets of aspirin or $2 tablets of NSAIDs/wk. CRC,
colorectal cancer; HPFS, Health Professionals Follow-Up Study; MET, metabolic equivalent; NHS, Nurses’ Health Study; NSAID, nonsteroidal anti-in-
flammatory drug; Q, quintile.
2Mean 6 SD (all such values).
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TABLE 2
RRs (95% CIs) of colorectal cancer and subsites according to quintiles of flavonoid intake1
RR (95% CI)
P-trend P-hetQ1 Q2 Q3 Q4 Q5
Flavonols
Colorectal
Men (1061 cases)
Age adjusted 1 (reference) 0.82 (0.67, 1.01) 0.88 (0.72, 1.07) 1.06 (0.88, 1.28) 0.93 (0.76, 1.12) 0.72
Multivariable 1 (reference) 0.83 (0.68, 1.02) 0.92 (0.75, 1.13) 1.12 (0.92, 1.36) 1.00 (0.82, 1.22) 0.25
Women (1458 cases)
Age adjusted 1 (reference) 0.96 (0.81, 1.13) 0.87 (0.74,1.03) 1.01 (0.86,1.19) 1.00 (0.85, 1.18) 0.57
Multivariable 1 (reference) 0.99 (0.84,1.17) 0.92 (0.78, 1.09) 1.07 (0.91,1.27) 1.06 (0.90, 1.26) 0.23
Pooled (2519 cases), multivariable 1(reference) 0.92 (0.78, 1.09) 0.92 (0.81, 1.05) 1.10 (0.97, 1.24) 1.04 (0.91, 1.18) 0.10 0.92
Colon
Men (831 cases), multivariable 1 (reference) 0.79 (0.62, 1.00) 0.94 (0.75, 1.18) 1.14 (0.92, 1.42) 1.02 (0.82, 1.28) 0.16
Women (1151 cases), multivariable 1 (reference) 0.95 (0.79, 1.15) 0.86 (0.71, 1.05) 1.02 (0.85, 1.23) 1.01 (0.83, 1.22) 0.54
Pooled (1982 cases), multivariable 1 (reference) 0.88 (0.73, 1.06) 0.90 (0.77, 1.04) 1.07 (0.93, 1.23) 1.01 (0.86, 1.17) 0.16 0.50
Rectum
Men (230 cases), multivariable 1 (reference) 0.96 (0.63, 1.47) 0.84 (0.54, 1.30) 1.05 (0.69, 1.61) 0.92 (0.59, 1.42) 0.86
Women (307 cases), multivariable 1 (reference) 1.13 (0.78, 1.66) 1.18 (0.81, 1.72) 1.31 (0.90, 1.89) 1.30 (0.90, 1.90) 0.15
Pooled (537 cases), multivariable 1(reference) 1.05 (0.80, 1.40) 1.01 (0.73, 1.41) 1.19 (0.90, 1.57) 1.11 (0.79, 1.57) 0.37 0.29
Flavones
Colorectal
Men (1061 cases)
Age adjusted 1 (reference) 0.96 (0.79, 1.17) 0.95 (0.78, 1.16) 0.91 (0.75, 1.11) 0.90 (0.74, 1.09) 0.26
Multivariable 1 (reference) 0.99 (0.81, 1.21) 1.03 (0.84, 1.25) 1.02 (0.83, 1.24) 1.04 (0.85, 1.27) 0.67
Women (1458 cases)
Age adjusted 1 (reference) 0.94 (0.80, 1.12) 0.94 (0.79, 1.11) 0.90 (0.76, 1.06) 0.90 (0.76, 1.06) 0.17
Multivariable 1 (reference) 0.99 (0.83, 1.17) 1.01 (0.85, 1.19) 0.98 (0.83, 1.17) 0.99 (0.83, 1.18) 0.91
Pooled (2519 cases), multivariable 1 (reference) 0.99 (0.87, 1.13) 1.02 (0.89, 1.16) 1.00 (0.88, 1.14) 1.01 (0.89, 1.15) 0.81 0.71
Colon
Men (831 cases), multivariable 1 (reference) 1.00 (0.80, 1.25) 1.04 (0.83, 1.30) 0.99 (0.79, 1.25) 1.12 (0.89, 1.40) 0.33
Women (1151 cases), multivariable 1 (reference) 0.97 (0.80, 1.18) 1.01 (0.84, 1.23) 1.00 (0.83, 1.22) 1.00 (0.83, 1.22) 0.66
Pooled (1982 cases), multivariable 1 (reference) 0.98 (0.85, 1.14) 1.02 (0.88, 1.18) 1.00 (0.86, 1.16) 1.07 (0.92, 1.24) 0.31 0.75
Rectum
Men (230 cases), multivariable 1 (reference) 0.96 (0.63, 1.45) 0.97 (0.64, 1.49) 1.10 (0.73, 1.67) 0.75 (0.47, 1.19) 0.34
Women (307 cases), multivariable 1 (reference) 1.05 (0.73, 1.49) 0.99 (0.69, 1.43) 0.92 (0.64, 1.34) 0.85 (0.58, 1.24) 0.27
Pooled (537 cases), multivariable 1 (reference) 1.01 (0.77, 1.32) 0.99 (0.75, 1.30) 1.00 (0.76, 1.32) 0.81 (0.60, 1.08) 0.15 0.87
Flavanones
Colorectal
Men (1061 cases)
Age adjusted 1 (reference) 1.05 (0.86, 1.28) 1.08 (0.89, 1.31) 0.99 (0.82, 1.21) 0.87 (0.71, 1.06) 0.08
Multivariable 1 (reference) 1.10 (0.90, 1.34) 1.17 (0.96, 1.43) 1.12 (0.91, 1.36) 1.02 (0.83, 1.25) 0.98
Women (1458 cases)
Age adjusted 1 (reference) 0.88 (0.74, 1.04) 0.90 (0.76, 1.06) 0.82 (0.69, 0.96) 0.84 (0.72, 1.00) 0.05
Multivariable 1 (reference) 0.90 (0.76, 1.07) 0.96 (0.81, 1.13) 0.89 (0.75, 1.05) 0.93 (0.78, 1.10) 0.48
Pooled (2519 cases), multivariable 1 (reference) 0.99 (0.82, 1.19) 1.05 (0.86, 1.28) 0.99 (0.79, 1.23) 0.96 (0.84, 1.10) 0.62 0.62
Colon
Men (831 cases), multivariable 1 (reference) 1.07 (0.85, 1.35) 1.18 (0.94, 1.47) 1.16 (0.92, 1.45) 1.01 (0.80, 1.28) 0.90
Women (1151 cases), multivariable 1 (reference) 0.87 (0.72, 1.05) 0.90 (0.74, 1.08) 0.91 (0.75, 1.09) 0.93 (0.77, 1.13) 0.77
Pooled (1982 cases), multivariable 1 (reference) 0.96 (0.78, 1.17) 1.02 (0.78, 1.33) 1.02 (0.80, 1.29) 0.96 (0.83, 1.12) 0.92 0.77
Rectum
Men (230 cases), multivariable 1 (reference) 1.15 (0.75, 1.75) 1.14 (0.75, 1.74) 0.94 (0.61, 1.47) 1.00 (0.64, 1.56) 0.66
Women (307 cases), multivariable 1 (reference) 1.04 (0.72, 1.49) 1.21 (0.85, 1.72) 0.82 (0.56, 1.21) 0.92 (0.63, 1.34) 0.34
Pooled (537 cases), multivariable 1 (reference) 1.08 (0.82, 1.42) 1.18 (0.90, 1.54) 0.87 (0.65, 1.17) 0.95 (0.71, 1.27) 0.33 0.69
Flavan-3-ols
Colorectal
Men (1061 cases)
Age adjusted 1 (reference) 0.94 (0.77, 1.15) 0.97 (0.80, 1.18) 1.00 (0.83, 1.21) 1.03 (0.85, 1.25) 0.48
Multivariable 1 (reference) 0.99 (0.81, 1.21) 1.05 (0.86, 1.28) 1.09 (0.89, 1.33) 1.12 (0.92, 1.36) 0.18
Women (1458 cases)
Age adjusted 1 (reference) 0.89 (0.75, 1.05) 0.88 (0.74, 1.03) 0.89 (0.76, 1.05) 0.99 (0.84, 1.16) 0.40
Multivariable 1 (reference) 0.93 (0.79, 1.11) 0.93 (0.79, 1.10) 0.94 (0.80, 1.11) 1.04 (0.88, 1.23) 0.25
(Continued)
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association between habitual intake of any flavonoid subclass in
relation to risk of CRC after multivariable adjustment. Thus,
these findings do not support the hypothesis that dietary flavo-
noid intake is associated with a lower risk of CRC. To our
knowledge, this is the largest prospective study relating habitual
intake of various subclasses of flavonoids to risk of CRC.
Epidemiologic data investigating flavonoid intake in relation
to CRC risk are conflicting. Inverse associations between fla-
vonols, flavan-3-ols, and anthocyanins and risk of CRC have been
observed in case-control studies (40). However, because flavo-
noids originate largely from plant-based foods and beverages (i.e.,
foods generally considered healthy), differential recall of these
foods by CRC cases compared with healthy control participants is
a likely source of bias in these studies. Our findings do not support
the findings from the secondary analysis of the Polyp Prevention
Trial, in which flavonol intake was associated with a lower risk of
advanced adenoma recurrence (16). If flavonols truly influence
the development of adenomas, we would expect that early fla-
vonol intake should have a stronger association with risk of CRC
than recent intake. However, the latency analysis gave only weak
support for flavonol intake 12–16 y before diagnosis being in-
versely associated with risk of CRC. Our findings also do not
confirm the previously observed associations between flavan-3-ol
intake and lower risk of rectal cancer (15) or urinary flavan-3-ols
and lower risk of colon cancer (17), but they are in line with
a meta-analysis including 3 prospective studies in which no
statistically significant association between flavan-3-ol intake
and risk of CRC was observed (40). Furthermore, the lack of
association between dietary intake of flavonols, flavones (10,
12, 14), and flavanones (41, 42) and risk of CRC observed
here is in line with previous prospective studies.
Our results showed no clear association between anthocyanin
intake and risk of CRC. In 2 previous prospective studies (41, 42),
no associations between anthocyanins and risk of CRC were
observed. It has been suggested that colonic microbial catabolites
of anthocyanins may mediate biological activities, including
anticarcinogenic properties (4). Because the catabolic yields
differ largely among individuals depending on the composition of
the gut microflora, it is possible that in an epidemiologic study
such as the present one, a reduced risk of CRC could have been
observed only in individuals with a certain microflora. The
growing research on the gut microbiome may enable future
epidemiologic studies to take this into account.
Of the major flavonoid food sources, tea, oranges, and blue-
berries were not associated with risk of CRC in our study. This is
in line with a recently published meta-analysis on tea (43) intake
in relation to risk of CRC and previous prospective studies in-
vestigating citrus fruit intake and risk of CRC (44, 45).We are not
aware of any prior prospective study investigating blueberry
intake in relation to CRC.
TABLE 2 (Continued )
RR (95% CI)
P-trend P-hetQ1 Q2 Q3 Q4 Q5
Pooled (2519 cases), multivariable 1 (reference) 0.96 (0.84, 1.09) 0.98 (0.86, 1.11) 1.00 (0.87, 1.15) 1.07 (0.95, 1.21) 0.09 0.65
Colon
Men (831 cases), multivariable 1 (reference) 1.07 (0.85, 1.34) 1.12 (0.89, 1.41) 1.16 (0.93, 1.46) 1.20 (0.96, 1.50) 0.13
Women (1151 cases), multivariable 1 (reference) 0.92 (0.77, 1.11) 0.95 (0.79, 1.14) 0.85 (0.70, 1.02) 1.02 (0.85, 1.23) 0.52
Pooled (1982 cases), multivariable 1 (reference) 0.98 (0.85, 1.13) 1.02 (0.87, 1.19) 0.99 (0.72, 1.35) 1.09 (0.93, 1.27) 0.16 0.39
Rectum
Men (230 cases), multivariable 1 (reference) 0.77 (0.51, 1.18) 0.85 (0.56, 1.28) 0.89 (0.59, 1.35) 0.90 (0.60, 1.35) 0.97
Women (307 cases), multivariable 1 (reference) 0.97 (0.67, 1.42) 0.85 (0.58, 1.25) 1.39 (0.98, 1.98) 1.13 (0.79, 1.63) 0.20
Pooled (537 cases), multivariable 1 (reference) 0.88 (0.66, 1.16) 0.85 (0.64, 1.13) 1.13 (0.73, 1.75) 1.02 (0.78, 1.34) 0.25 0.50
Anthocyanins
Colorectal
Men (1061 cases)
Age adjusted 1 (reference) 0.83 (0.69, 1.01) 0.92 (0.76, 1.10) 0.84 (0.69, 1.02) 0.78 (0.64, 0.94) 0.03
Multivariable 1 (reference) 0.88 (0.73, 1.07) 0.99 (0.82, 1.20) 0.94 (0.77, 1.14) 0.88 (0.72, 1.08) 0.36
Women (1458 cases)
Age adjusted 1 (reference) 0.92 (0.78, 1.09) 1.01 (0.86, 1.19) 0.91 (0.77, 1.08) 0.96 (0.81, 1.13) 0.71
Multivariable 1 (reference) 0.96 (0.81, 1.14) 1.08 (0.92, 1.28) 0.99 (0.84, 1.18) 1.08 (0.90, 1.28) 0.35
Pooled (2519 cases), multivariable 1 (reference) 0.93 (0.82, 1.05) 1.04 (0.92, 1.18) 0.97 (0.85, 1.10) 0.98 (0.81, 1.19) 0.98 0.19
Colon
Men (831 cases), multivariable 1 (reference) 0.92 (0.74, 1.14) 0.98 (0.79, 1.21) 1.00 (0.81, 1.25) 0.85 (0.67, 1.07) 0.26
Women (1151 cases), multivariable 1 (reference) 0.96 (0.79, 1.15) 1.06 (0.88, 1.28) 0.98 (0.81, 1.19) 1.04 (0.86, 1.27) 0.57
Pooled (1982 cases), multivariable 1 (reference) 0.94 (0.81, 1.08) 1.02 (0.89, 1.18) 0.99 (0.86, 1.15) 0.95 (0.77, 1.16) 0.76 0.23
Rectum
Men (230 cases), multivariable 1 (reference) 0.74 (0.48, 1.13) 1.01 (0.67, 1.50) 0.70 (0.45, 1.10) 0.99 (0.65, 1.50) 0.83
Women (307 cases), multivariable 1 (reference) 1.00 (0.69, 1.45) 1.17 (0.81, 1.68) 1.04 (0.71, 1.52) 1.04 (0.71, 1.52) 0.35
Pooled (537 cases), multivariable 1 (reference) 0.88 (0.66, 1.17) 1.09 (0.83, 1.43) 0.87 (0.60, 1.27) 1.10 (0.83, 1.45) 0.40 0.63
1Multivariable relative risks were adjusted for age (in months), pack-years of smoking before age 30 y (0, 1–4, 5–10, or .10 pack-years), history of
colorectal cancer in a parent or sibling (yes or no), history of endoscopy (yes or no), regular aspirin use (yes or no), BMI (in kg/m2; ,25, 25 to ,30, $30),
physical activity (low, medium, high), alcohol consumption (0 to,5, 5 to,10, 10 to,15, or$15 g/d), total calories (quintiles), energy-adjusted total vitamin
D intake (quintiles), total calcium intake (quintiles), red meat intake (quintiles), and processed meat intake (quintiles). P-het, P value for heterogeneity by sex;
Q, quintile.
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Although our study and the majority of prospective studies do
not support an inverse association between dietary intake of
flavonoid subclasses and risk of CRC, the evidence from ex-
perimental studies remains biologically plausible. In in vitro
studies, flavonoids, especially flavan-3-ols and flavonols from
tea, have been shown to inhibit growth of human colon cancer cell
lines (46). In addition, it has been shown that flavan-3-ols from
apples can reactivate silenced tumor suppressor genes in CRC
cells (47). However, the evidence on protective effects of fla-
vonoids against colon carcinogenesis is less conclusive in animal
studies (47). It remains unclear whether anticarcinogenic effects
of flavonoid subclasses observed in experimental studies play
a relevant role in the etiology of CRC in humans because the
flavonoid concentrations used in in vitro studies or doses used in
in vivo studies can hardly be reached through habitual dietary
intake (3). For example, studies investigating the effect of dietary
intake of the flavonol quercetin on tumor formation in mice
typically used a quercetin concentration of 2% in the diet (48).
Also, many human intervention studies investigating the effect of
flavonoid intake on intermediary markers such as antioxidant
biomarkers or carcinogenesis markers such as DNA damage used
experimental doses that are difficult to attain with habitual diet
(e.g., daily doses of 50–500 mg quercetin) (49). For comparison,
median intakes of flavonols were 18 mg/d in the HPFS and
15 mg/d in the NHS. Bioavailability studies have shown that
a 50-mg dose of quercetin leads to plasma concentrations of
0.75–1.5 mmol/L quercetin (49), which is 10-fold lower than the
typical dose of 10 mM used in in vitro studies with colon cancer
cell lines (2). However, because a substantial proportion of di-
etary flavonoids reaches the colon (4), it is expected that at least
some of the biological activity, including potential anticarcino-
genic properties, may act locally through colonic metabolites,
but these effects are difficult to quantify.
Our study has several limitations. First, the FFQ was not
specifically designed to investigate flavonoid intakes. Therefore,
some foods rich in flavonoids (e.g., herbs) were missing from the
FFQ, and foods with varying flavonoid contents may have been
subsumed within one food item (e.g., apples and pears). Fur-
thermore, flavonoid contents may vary depending on species,
seasonal variation, maturity, and various agricultural, food-
processing, and storage practices. These factors may have con-
tributed to misclassification of flavonoid intakes, which may have
led to an attenuation of observed associations, and thus may have
obscured the detection of weak associations. Another limitation
lies in the multiple comparisons that were made during this
hypothesis-driven data analysis. We also acknowledge that our
findings are not necessarily generalizable to other populations.
Strengths of our study include the prospective study design; the
repeated dietary intake assessment, which allowed for estimation
of long-term intake as well as investigation of different latencies;
and the large number of cases, which enabled us to investigate
CRC individually according to location. Furthermore, the de-
tailed data on potentially confounding factors are a strength and
turned out to be important, because some of the associations that
were observed in age-adjusted models were largely attenuated in
the fully adjusted models.
In conclusion, our study findings do not support the hypothesis
that diets high in flavonoids may reduce risk of CRC. The lack of
association may be related to the low habitual intake of flavo-
noids, interindividual variation of colonic microbial catabolite
production, and/or misclassification of flavonoid intake. Epide-
miologic studies employing biomarkers of flavonoids may help
elucidate whether the anticarcinogenic effects of flavonoids that
have been observed in experimental studies may also be relevant
in humans with habitual dietary intake.
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